ES2530769T3 - Methods for activation of T cells in vivo by dendritic cells pulsed with antigen - Google Patents

Methods for activation of T cells in vivo by dendritic cells pulsed with antigen Download PDF

Info

Publication number
ES2530769T3
ES2530769T3 ES95923042T ES95923042T ES2530769T3 ES 2530769 T3 ES2530769 T3 ES 2530769T3 ES 95923042 T ES95923042 T ES 95923042T ES 95923042 T ES95923042 T ES 95923042T ES 2530769 T3 ES2530769 T3 ES 2530769T3
Authority
ES
Spain
Prior art keywords
antigen
cells
vivo
activation
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95923042T
Other languages
Spanish (es)
Inventor
Edgar G Engleman
Ronald Levy
Frank Hsu
Claudia Benike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of ES2530769T3 publication Critical patent/ES2530769T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de células dendríticas humanas aisladas que se han pulsado con un antígeno in vitro en la producción de un medicamento para activar una respuesta inmunitaria a un antígeno en un paciente humano.Use of isolated human dendritic cells that have been pulsed with an antigen in vitro in the production of a drug to activate an immune response to an antigen in a human patient.

ES95923042T 1994-06-14 1995-06-13 Methods for activation of T cells in vivo by dendritic cells pulsed with antigen Expired - Lifetime ES2530769T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25977494A 1994-06-14 1994-06-14
PCT/US1995/007461 WO1995034638A1 (en) 1994-06-14 1995-06-13 Methods for in vivo t cell activation by antigen-pulsed dendritic cells

Publications (1)

Publication Number Publication Date
ES2530769T3 true ES2530769T3 (en) 2015-03-05

Family

ID=22986324

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95923042T Expired - Lifetime ES2530769T3 (en) 1994-06-14 1995-06-13 Methods for activation of T cells in vivo by dendritic cells pulsed with antigen

Country Status (8)

Country Link
EP (1) EP0765386B1 (en)
JP (1) JPH10504284A (en)
AU (1) AU710783B2 (en)
CA (1) CA2192655A1 (en)
DK (1) DK0765386T3 (en)
ES (1) ES2530769T3 (en)
PT (1) PT765386E (en)
WO (1) WO1995034638A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (en) * 1992-04-01 2004-12-02 The Rockefeller University METHOD FOR THE VITRO CULTIVATION OF DENDRITIC PROCUREMENT CELLS AND THE USE THEREOF FOR IMMUNOGENOUS PRODUCTION
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
AU1152397A (en) * 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
JP2000508628A (en) * 1996-03-22 2000-07-11 エール・ユニバーシティ Methods for inducing an immune response in a subject
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6194204B1 (en) 1996-08-02 2001-02-27 Center For Blood Research, Inc. Enrichment of dendritic cells from blood
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
ATE229810T1 (en) * 1996-10-11 2003-01-15 Univ California CANCER IMMUNOTHERAPY USING TUMOR CELLS COMBINED WITH LYMPHOCYTE MIXTURES
CA2289742C (en) * 1997-05-08 2013-07-16 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
EP0983345A1 (en) 1997-05-21 2000-03-08 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating t cells
US6713250B1 (en) 1997-08-08 2004-03-30 The Research Foundation Of State University Of New York Identification of human allergens and T-lymphocyte antigens in vitro
DE69840739D1 (en) 1997-10-27 2009-05-28 Merix Bioscience Inc Method and composition for the production of mature dendritic cells
AU2872199A (en) 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
FR2775692B1 (en) * 1998-03-03 2000-06-16 Roussy Inst Gustave METHODS FOR ACTIVATING NATURAL KILLER (NK) CELLS AND MEANS OF IMPLEMENTATION
FR2782524B1 (en) * 1998-08-21 2002-07-19 Roussy Inst Gustave METHODS OF ACTIVATION OF NATURAL KILLER CELLS (NK) AND MEANS OF IMPLEMENTATION
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
WO1999063050A2 (en) * 1998-06-02 1999-12-09 Dendreon Corporation Method for preparation and in vivo administration of antigen presenting cell composition
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
IT1312570B1 (en) * 1999-05-28 2002-04-22 Genera Spa METHOD FOR TRANSFER OF DENDRITIC CELL ANTIGENS.
WO2001040308A1 (en) * 1999-12-03 2001-06-07 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Dendritic cell-specific antibodies
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US6984389B2 (en) * 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
WO2008055354A1 (en) * 2006-11-10 2008-05-15 Université de Montréal Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods
DE102009017827A1 (en) * 2009-04-20 2010-10-21 Sasol Germany Gmbh Process for the preparation of branched hydrocarbons from fatty alcohols and use of such produced hydrocarbons
BRPI0905536A2 (en) * 2009-12-16 2011-08-16 Fundacao De Amparo A Pesquisa maturation process of autologous dendritic cells
JP5995247B2 (en) 2011-02-23 2016-09-21 国立大学法人京都大学 Method for producing dendritic cells from pluripotent stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
AU687733B2 (en) * 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
AU4678993A (en) * 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells

Also Published As

Publication number Publication date
WO1995034638A1 (en) 1995-12-21
DK0765386T3 (en) 2015-01-26
CA2192655A1 (en) 1995-12-21
EP0765386B1 (en) 2014-12-10
EP0765386A4 (en) 1998-01-07
PT765386E (en) 2015-02-06
AU710783B2 (en) 1999-09-30
JPH10504284A (en) 1998-04-28
AU2772595A (en) 1996-01-05
EP0765386A1 (en) 1997-04-02

Similar Documents

Publication Publication Date Title
ES2530769T3 (en) Methods for activation of T cells in vivo by dendritic cells pulsed with antigen
ES2057124T3 (en) THERAPEUTIC PRODUCT FOR THE TREATMENT OF PERI- OR POST-MENOPAUSIC STATES.
EP2377548A3 (en) Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
ES2099056T3 (en) STRAINS OF LACTOBACILLUS OF HUMAN ORIGIN, ITS COMPOSITIONS AND USES OF THEM.
EA199800946A1 (en) CONCENTRATED ANTIBODY PREPARATION
GEP20022648B (en) Method for Inducing T Cell Tolerance to a Tissue or Organ Graft
BR9907189A (en) Products of the lipid fraction of the sea cucumber carotenoid and methods of use
NO331101B1 (en) In vitro method for expressing an antigen molecule and antigen molecule and a photosensitizing agent for use in expressing the antigen molecule.
ES2053815T3 (en) PHARMACEUTICAL PREPARATION WITH PROLONGED RELEASE OF A DIHYDROPYRIDINE AND AN ANTAGONIST OF A BETA-ADRENORECEPTOR AND A PROCEDURE FOR ITS PREPARATION.
ES2142829T3 (en) DEVICES TO CARRY OUT AN INTRALUMINAL PROCEDURE.
AU6998791A (en) Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
ATE491465T1 (en) METHOD FOR OBTAINING ACTIVATED T CELLS AND ANTIGEN-PRESENTING CELLS INCUBATED WITH ANTIGEN
ES2170259T3 (en) EMPLOYMENT OF LIPIDS AS AUXILIARY AGENTS IN OBTAINING SOLID PHARMACEUTICAL FORMS ACCORDING TO THE FUSION EXTRUSION PROCEDURE.
ES2144239T3 (en) DERIVATIVES OF VITAMIN D WITH C-25 SUBSTITUTES, PROCEDURE FOR THE PREPARATION, INTERMEDIATE PRODUCTS AND THE USE FOR THE PREPARATION OF MEDICINES.
SE9003718D0 (en) IMPLANT WITH CURRENT PASSAGE
FI870808L (en) 9-ALPHA, 11-BETA-SUBSTITUERADE OCH 11-BETA-SUBSTITUERADE ESTRANER.
AR039186A1 (en) INDEPENDENT MOTHER CELLS PROGRAMMABLE OF MONOCITAR ORIGIN, ITS OBTAINING AND USE
PT1131408E (en) OLIGOSACARIDO-ALDONICOS ACIDS AND THEIR USES TOPIC
ATE422893T1 (en) MANNOSE RECEPTOR-BEARING CELL LINE AND ANTIGEN COMPOSITION
ES2156215T3 (en) USE OF A CONJUGATE IN THE TREATMENT AND / OR DIAGNOSIS OF INFLAMMATORY DISEASES.
CY1104971T1 (en) PREPARATION OF APOINIDOTIDE AND G-CSF AND ITS USE TO STIMULATE HEMAPOPOIETIC PROGENORS
IL122755A0 (en) Preparations and methods for the treatment of T cell mediated diseases
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
ES2172558T3 (en) LUBRICANT COMPATIBLE WITH RADIATIONS FOR MEDICAL DEVICES.